We are the leading Shuanghuanglian-based cold medicines brand in China in in terms of sales revenue in 2016 according to the Frost & Sullivan Report, and Shuanghuanglian Oral Solution is the largest drug category in terms of revenue in the PCM cold medicine market of 2016. In the same year and according to the same report, we ranked 8th in in terms of sales revenue among all the PCM cold medicines manufacturers.
In addition to offering our core products Shuanghuanglian-based cold medicines, we are engaged in the research, development, production and sales of a wide variety of PCMs and chemical medicines for the treatments of cold and fever, cardiovascular diseases and anemia, many of which also enjoy a leading market share in their respective markets.
Our expertise lies in high quality OTC and prescription PCM in modern dosage forms. As of December 31, 2016, our product portfolio comprises 27 types of pharmaceutical products, all under our Fusen brand. Going forward, we will continue to focus the production and sales of our major products, especially Shuanghuanglian Oral Solution and Shuanghuanglian Injection, while continue to update and expand our product portfolio to stay current with market demand and competitions.
Our product portfolio can be categorized into: (i) Shuanghuanglian Oral Solution (); (ii) Shuanghuanglian Injection (); and (iii) others, including PCMs such as Chaihu Injection () and western medicine products such as Flunarizine Hydrochloride Capsules (), Compound Ferrous Sulfate Granules () and Clarithromycin Sustained Release Tablets (). The table below sets forth a breakdown of our revenue by product categories for the periods indicated.